Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

EXPLAINED: Bridgebio pharma s return on capital employed insights - The Real Truth

Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter. BridgeBio Pharma collected $12.89 million in revenue during Q4, but reported earnings showed a $152.28 million loss.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.